Ieq Capital LLC Grows Stock Position in Pfizer Inc. $PFE

Ieq Capital LLC lifted its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 59.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 742,927 shares of the biopharmaceutical company’s stock after purchasing an additional 276,649 shares during the period. Ieq Capital LLC’s holdings in Pfizer were worth $17,890,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in PFE. Godfrey Financial Associates Inc. purchased a new stake in Pfizer during the fourth quarter valued at approximately $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $26,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new stake in shares of Pfizer in the 4th quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors.

Get Pfizer alerts:

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Guggenheim reduced their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Read Our Latest Report on PFE

Pfizer Stock Down 0.2%

Shares of PFE stock opened at $28.00 on Monday. The company has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company’s fifty day moving average price is $25.30 and its 200-day moving average price is $26.25. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Featured Stories

• Five stocks we like better than Pfizer
• VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
• 3 Closed-End Funds to Maximize Dividend Payments
• Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
• $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.